
Streeting should stand firm in face of doctors' risible demands
No country can claim to be in the forefront of democracy and development unless it can ensure the health of its citizens. Whatever its woes — and they are many — the National Health Service does keep most Britons in better health than many people on other continents. Partly that is thanks to pioneering excellence in medical research. And partly it is the result of a long tradition of top surgeons and physicians whose skills underpin specialist units attracting doctors from overseas. The consultants know it. They are proud of it. And, to their discredit, they are ready nowadays to exploit it.
NHS consultants earn, on average, £145,000 a year. It may not be the salary of an investment banker. But it is considerably more than most people are paid. And there is ample opportunity to supplement this salary with private practice and filling in as a locum at the going rate of £200 an hour. Consultants have been awarded a pay increase of 4 per cent for the coming year, a figure above inflation. The British Medical Association, the doctors' union, has described this as an 'insult'. It insists that a pay rise of 35 per cent over the next three years is needed to restore consultant pay to 2008 levels in real terms. Otherwise, the BMA says, it will support a strike if an 'indicative ballot' shows that this is what senior doctors want.
The consultants' claim is risible. It is not only unaffordable in today's straitened times and given the parlous state of NHS finances; it is based on the threat of holding the health, and sometimes the lives, of thousands of patients to ransom. It is a maximalist demand, backed by possible strike action, similar to the bullying approach of the rail unions. Consultants ought to be able to see that their claim has far less validity or public support than the claims by nurses and resident — once known as junior — doctors. They, too, insist that their pay needs to catch up with what they once enjoyed. They, too, risk losing public sympathy, following earlier strike action. But millions of Britons have seen their take-home pay fall in recent years. Comparisons do not help consultants.
Famously, Aneurin Bevan, the architect of the NHS, bought off consultants opposed to his proposals for a state scheme, saying that he had 'stuffed their mouths with gold'. And since 1948 they have enjoyed this well-funded quasi-independence from state control, with generous state pensions. They have also enjoyed the fruits of expensive training, provided largely by the state in Britain's medical schools. Doctors, like everyone nowadays, are obliged to pay back their tuition fees — but many will not do so for years. An alarming number will never do so; on qualification they look for more lucrative contracts abroad, often in Australia. As a result Britain has partly depended on an inflow of doctors trained overseas, largely in India, a situation benefiting neither country.
In the long term, the tight restriction on the numbers enrolling in medical schools should be eased; a developed country should never risk a doctor shortage. Also in the long term, doctors, especially consultants, should be compelled, by legislation if necessary, to devote a defined period of their careers to the NHS and serve in areas of greatest need. Other countries make provision for nationwide coverage. The immediate challenge, however, is pay. Wes Streeting, the health secretary, is holding talks with the BMA. He must stand firm in resisting its absurd new demands.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


The Independent
31 minutes ago
- The Independent
Weight loss pill shows promise in new trial
A new weight loss medication, which can be offered by injection or tablet, can help patients lose a significant amount weight, studies suggest. An early study have found that people who received higher doses of amycretin as a weekly jab lost 24.3% of their body weight after 36 weeks of treatment. And initial trials assessing a tablet form of the drug also showed promising results, with patients taking daily tablets losing an average of 13.1% of their body weight after 12 weeks. Weight loss jabs have been hailed as transformative by NHS leaders. But injections come with additional work for over-stretched health services so tablet forms of medication may offer a new hope for the millions of people looking to lose weight. It has been estimated that around 1.5 million Britons are having weight loss jabs, which have been either prescribed through specialist weight loss services or private prescriptions. GPs will be able to dish out that jabs from next week. Amycretin, made by Novo Nordisk, helps to control blood sugar and appetite by targeting two specific receptors in the body – GLP-1 and the amylin receptor. An early trial in 125 adults testing weekly injections of amycretin, which has been published in The Lancet, found that those taking the highest dosage (60mg) lost 24.3% after 36 weeks of treatment. It also showed signs in improving blood sugar levels. Side effects included nausea and vomiting and were mostly mild to moderate and resolved by the end of treatment. 'These phase 1b/2a data support the potential of once-weekly subcutaneous amycretin as a therapeutic for people living with overweight or obesity,' the authors wrote. 'Amycretin appeared safe and tolerable, and there were significant reductions in body weight after 36 weeks of treatment.' The second early trial, published in the same journal, assessed amycretin in tablet form in 144 people over 12 weeks. There were mild to moderate side effects including loss of appetite, nausea and vomiting. Researchers found that people taking the highest dose of 100mg per day, lost 13.1% of their body weight over four months. The authors wrote: 'Amycretin effectively lowered body weight and improved metabolic and glycaemic parameters in people with overweight or obesity. 'Longer studies with more participants are warranted for evaluation of the safety and efficacy of amycretin in individuals living with obesity and type 2 diabetes, and to optimise the dosing regimen.' The studies were also presented at the American Diabetes Association's Scientific Sessions in Chicago, in the US. It comes as a separate study, which was published at the same meeting, examined the effects of weight loss jab Wegovy at higher doses. Researchers found that giving patients 7.2mg of Wegovy, also known as semaglutide, once a week led to an average weight loss of 20.7%, with a third of participants losing 25% or more of their body weight after 72 weeks.


South Wales Guardian
an hour ago
- South Wales Guardian
Weight loss pill shows promise in new trial
An early study have found that people who received higher doses of amycretin as a weekly jab lost 24.3% of their body weight after 36 weeks of treatment. And initial trials assessing a tablet form of the drug also showed promising results, with patients taking daily tablets losing an average of 13.1% of their body weight after 12 weeks. Weight loss jabs have been hailed as transformative by NHS leaders. But injections come with additional work for over-stretched health services so tablet forms of medication may offer a new hope for the millions of people looking to lose weight. It has been estimated that around 1.5 million Britons are having weight loss jabs, which have been either prescribed through specialist weight loss services or private prescriptions. GPs will be able to dish out that jabs from next week. Amycretin, made by Novo Nordisk, helps to control blood sugar and appetite by targeting two specific receptors in the body – GLP-1 and the amylin receptor. An early trial in 125 adults testing weekly injections of amycretin, which has been published in The Lancet, found that those taking the highest dosage (60mg) lost 24.3% after 36 weeks of treatment. It also showed signs in improving blood sugar levels. Side effects included nausea and vomiting and were mostly mild to moderate and resolved by the end of treatment. 'These phase 1b/2a data support the potential of once-weekly subcutaneous amycretin as a therapeutic for people living with overweight or obesity,' the authors wrote. 'Amycretin appeared safe and tolerable, and there were significant reductions in body weight after 36 weeks of treatment.' The second early trial, published in the same journal, assessed amycretin in tablet form in 144 people over 12 weeks. There were mild to moderate side effects including loss of appetite, nausea and vomiting. Researchers found that people taking the highest dose of 100mg per day, lost 13.1% of their body weight over four months. The authors wrote: 'Amycretin effectively lowered body weight and improved metabolic and glycaemic parameters in people with overweight or obesity. 'Longer studies with more participants are warranted for evaluation of the safety and efficacy of amycretin in individuals living with obesity and type 2 diabetes, and to optimise the dosing regimen.' The studies were also presented at the American Diabetes Association's Scientific Sessions in Chicago, in the US. It comes as a separate study, which was published at the same meeting, examined the effects of weight loss jab Wegovy at higher doses. Researchers found that giving patients 7.2mg of Wegovy, also known as semaglutide, once a week led to an average weight loss of 20.7%, with a third of participants losing 25% or more of their body weight after 72 weeks.


Daily Mail
an hour ago
- Daily Mail
Erectile dysfunction drug Viagra has surprise new health benefit, scientists find - offering new hope to 3million ageing Britons
A surprising new health benefit has emerged from the sex drug Viagra - which means three million ageing Britons can now also enjoy a harder skull. The little blue tablet was found to increase the production of vital bone cells, preventing back pain and fractures in old age. Sildenafil - also known as Viagra - can help human stem cells transform into osteoblasts which help the human skeleton regenerate as it is completely replaced roughly once every 10 years. As humans get older, they lose more bone than is built, increasing the risk of breaks or osteoporosis, which makes bones brittle and painful. Follow-up tests on mice by Peking University also suggested a prevention of bone loss. Dr Menglong Hu and Dr Likun Wu told MailOnline: 'Our findings offer new insights into the physiological effects of the medicine. 'Sildenafil enhanced stem cell osteogenic differentiation and inhibited bone loss — it may usefully treat osteoporosis.' Viagra was invented as a heart drug in the 1980s before being found to help with erectile dysfunction. Some studies suggest it may also help reduce the risk of dementia. However, the have been cautions over the years that the drug could have some negative side effects, in particular if taken too much. A large quantity of the drug could result in a painful, 'uncomfortably and disproportionately large erection' called a priapism which could go on for hours. Some experts also found regularly taking the common drug may raise the risk of three serious eye conditions. Common side effects may include headaches, hot flushes, nausea, indigestion, dizziness and a stuffy nose. Nearly half of men between the ages of 40 and 70 suffer from erectile dysfunction in the UK - this is more than 4.5 million people. Though, reports suggest Viagra is now even becoming increasingly popular with younger individuals in their 20s and 30s. Last year, it emerged Viagra may help prevent dementia by boosting blood flow in the brain. 'This is the first trial to show that sildenafil gets into the blood vessels in the brain in people with this condition, improving blood flow and how responsive these blood vessels are,'Dr Alastair Webb, a neurologist and study author at Oxford University said.